GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (STU:5GH) » Definitions » PB Ratio

Guardant Health (STU:5GH) PB Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Guardant Health PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-14), Guardant Health's share price is €33.05. Guardant Health's Book Value per Share for the quarter that ended in Sep. 2024 was €-0.44. Hence, Guardant Health's PB Ratio of today is .

The historical rank and industry rank for Guardant Health's PB Ratio or its related term are showing as below:

During the past 8 years, Guardant Health's highest PB Ratio was 54.74. The lowest was 6.43. And the median was 13.26.

STU:5GH's PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.195
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Guardant Health's average Book Value Per Share Growth Rate was -125.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -53.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -36.80% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Guardant Health was 4.00% per year. The lowest was -58.90% per year. And the median was -53.50% per year.

Back to Basics: PB Ratio


Guardant Health PB Ratio Historical Data

The historical data trend for Guardant Health's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health PB Ratio Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - - 15.08 45.12 20.90

Guardant Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.54 20.90 31.98 - -

Competitive Comparison of Guardant Health's PB Ratio

For the Diagnostics & Research subindustry, Guardant Health's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's PB Ratio distribution charts can be found below:

* The bar in red indicates where Guardant Health's PB Ratio falls into.



Guardant Health PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Guardant Health's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=33.05/-0.44
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Guardant Health  (STU:5GH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Guardant Health PB Ratio Related Terms

Thank you for viewing the detailed overview of Guardant Health's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Headlines

No Headlines